At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 407 enrolled
Drug / intervention
sumatriptan and naproxen sodium combination tablet +2 moredrug
Likely dose
sumatriptan and naproxen sodium combination tablet 85mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults
In Brief
A Phase 4 clinical trial evaluating sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and 1 other intervention for Migraine Disorders. Completed, enrolled 407 participants across 49 sites.
Detailed Summary
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionNov 2009
TodayJul 2026
First PostedNov 18, 2008
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.6 years ago
Interventions
sumatriptan and naproxen sodium combination tabletdrug
sumatriptan 85mg and naproxen sodium 500mg
sumatriptan tabletdrug
sumatriptan 85mg
naproxen sodium tabletdrug
Naproxen sodium 500mg